Incyte (ICYT) Q4 Earnings Surge 15%, Beats Analyst Estimates

Incyte Corporation (ICYT) reported Q4 net income of $293 million, a 15% increase from $255 million in the same period of 2025, driven by strong sales of its key oncology therapies. The company beat analyst estimates by a margin of $0.03 per share, with revenue rising 10% year-over-year to $2.41 billion. Management attributed the results to continued demand for Revlimid and Carmofur, and to the successful launch of new formulations of key products. The stock closed at $45.32 on February 9, 2026, up 4.2% on the earnings release.